Latest Regulatory News

Charter Hall Wholesale Management Limited has extended its off-market takeover offer for Hotel Property Investments, pushing the closing date to March 14, 2025. The offer is now unconditional, having cleared all defeating conditions.

Fin Resources Limited reports steady progress in lithium and uranium exploration across its Canadian and Australian projects, while managing a lean cash position and evaluating funding options.

Pacific Nickel Mines Limited has paused its Kolosori Nickel Project due to operational setbacks and a challenging nickel price environment, entering voluntary suspension while negotiating critical financing with Glencore.

Western Gold Resources Limited has secured expanded mining approvals, confirmed strong metallurgical recoveries, and updated its mineral resource estimate at the Gold Duke Project, positioning the company for a transition to production.

Magnis Energy Technologies reports ongoing progress on its Nachu Graphite Project while grappling with Imperium3’s bankruptcy and a prolonged ASX trading suspension.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Classic Minerals Limited has agreed to sell its Kat Gap gold tenements to Bain Global Resources for A$7 million, aiming to reduce debt and refocus on other exploration projects. The deal awaits shareholder approval and regulatory clearances.

South Harz Potash Limited has made significant strides in acquiring the Sollstedt mine and secured approximately A$2.2 million in new equity, positioning itself to advance the Ohmgebirge project amid a strengthening potash market.

Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.

Elsight reported a robust 32% increase in annual revenue for 2024, driven by a strategic pivot towards the defense sector, which now accounts for over half of its total revenue. The company’s expanding customer base and debt elimination position it well for growth in 2025.

Range International Limited has appointed Russell Kennett as its new CEO, marking a pivotal step in the company’s growth strategy. The move comes alongside an update to Executive Chairman Richard Jenkins’ remuneration, underscoring leadership continuity.